Is Thymosin Alpha-1 Legal in Wisconsin? How to Access It Legally

What Is Thymosin Alpha-1 and Why Does Legal Status Matter?

Thymosin Alpha-1 is a 28-amino-acid peptide derived from thymosin fraction 5, first isolated by Allan Goldstein, Ph.D., at George Washington University in the 1970s. It modulates T-cell maturation, dendritic cell activity, and innate immune signaling through Toll-like receptors 7 and 9. Research in Clinical Immunology confirmed its capacity to upregulate MHC class I antigen expression and shift cytokine profiles toward a Th1 phenotype.

Because TA-1 has no FDA-approved finished-drug application in the United States, its legal status depends entirely on federal compounding law and the policies of individual state pharmacy boards. Getting this wrong carries real consequences: purchasing TA-1 from an unregulated overseas supplier may expose patients to adulterated product, and prescribers who dispense outside compounding law risk DEA or state board sanction.

The Immunological Basis for Clinical Interest

TA-1 binds Toll-like receptor 9 to stimulate plasmacytoid dendritic cells, increasing interferon-alpha output. A randomized trial in 361 patients with chronic hepatitis B (Hepatology, 2005) showed that 1.6 mg subcutaneous TA-1 twice weekly for 52 weeks produced a hepatitis B e-antigen seroconversion rate of 40% versus 11% for control (P<0.001). That trial formed part of the regulatory package for thymalfasin's approval in countries outside the US.

A separate placebo-controlled study of 73 sepsis patients found that TA-1 reduced 28-day mortality from 35% to 26% compared with standard of care, though the confidence interval crossed 1.0, indicating the finding requires replication in a larger cohort. See the PubMed record here.

TA-1 in Oncology and Viral Illness

Interest in TA-1 expanded significantly after a 2020 randomized trial published in the Journal of Infection (N=120 severe COVID-19 patients) showed that adjunctive TA-1 reduced 28-day mortality by 11 percentage points compared with standard of care. Full trial record on PubMed. A meta-analysis of 14 randomized trials (N=1,279) across hepatitis B, hepatitis C, and HIV contexts found a pooled odds ratio of 2.31 for viral clearance with TA-1 versus control. See the meta-analysis.

These data explain why US clinicians, particularly those working in integrative medicine and immunology, seek legal access for off-label compounding.

Federal Legal Framework: FDA Status of Thymosin Alpha-1

No Approved NDA or BLA

The FDA has not approved any new drug application (NDA) or biologics license application (BLA) for Thymosin Alpha-1 in the United States as of January 2025. The FDA drug database contains no entry for thymalfasin or thymosin alpha-1 as an approved finished product. This absence of approval does not make the compound illegal per se; it means the compound must follow one of two legal access paths: an investigational new drug (IND) application or compounding under 503A/503B.

The 503A Compounding Pathway

Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) permits a state-licensed pharmacist to compound a drug product for an identified individual patient based on a valid prescription from a licensed practitioner, provided the bulk drug substance meets USP or NF standards or appears on the FDA's 503A "bulks list" of substances that may be used in compounding. The FDA's current 503A policy page clarifies this framework.

TA-1 has not been nominated to and placed on the FDA's 503A bulk substances "Category 1" list of approved substances, nor has it been placed on the prohibited "Category 2" list that would ban its use in compounding. This ambiguous middle status, being neither explicitly permitted nor explicitly prohibited, is what practitioners mean when they describe TA-1 as occupying a "gray area." As the FDA has stated in its compounding guidance documents, substances not yet evaluated remain compoundable under existing practice while the agency continues its review process.

The 503B Outsourcing Facility Pathway

Section 503B (21 U.S.C. 353b) created a category of "outsourcing facilities" that may compound drugs without patient-specific prescriptions for office use, provided they register with the FDA, follow current good manufacturing practice (CGMP), and use only bulk substances from the 503B bulks list or drugs that are essentially a copy of an FDA-approved product. The FDA's 503B page lists registered outsourcing facilities and currently nominated bulk substances.

TA-1 is not currently on the FDA's final 503B bulk substances list, which limits the 503B pathway. A 503A community pharmacy remains the more straightforward legal route for most patients.

FDA Bulk Drug Substances Enforcement Posture

The FDA's Office of Pharmaceutical Quality conducts inspections of 503A pharmacies and has issued warning letters to compounders producing substances on Category 2 prohibited lists. A reviewed set of those warning letters is publicly available. TA-1 does not appear in any publicly available warning letter as of the date of this article's review, which suggests the agency has not prioritized enforcement action against 503A pharmacies compounding it for individual patients under valid prescriptions.

Wisconsin State Law and Pharmacy Board Rules

No Additional State-Level Prohibition

Wisconsin does not have a statute or pharmacy board rule that independently prohibits the compounding or dispensing of Thymosin Alpha-1 beyond the requirements of federal law. The Wisconsin Pharmacy Examining Board, operating under Wis. Stat. Ch. 450, regulates pharmacist licensure, pharmacy practice standards, and compounding quality. Those rules require that compounding pharmacies comply with USP Chapter 797 (sterile preparations) and Chapter 795 (non-sterile preparations), both of which set quality and beyond-use dating standards that apply to any compounded sterile peptide.

A Wisconsin-licensed prescriber ordering a compounded TA-1 preparation from a compliant 503A pharmacy operates fully within state law, provided:

• A valid prescriber-patient relationship exists under Wisconsin Medical Practice Act (Wis. Stat. Ch. 448).
• The prescription specifies patient name, compound, strength, route, and quantity.
• The dispensing pharmacy is licensed in Wisconsin or ships under a valid out-of-state pharmacy license accepted by the Wisconsin Pharmacy Examining Board.

Telehealth Prescribing in Wisconsin

Wisconsin adopted synchronous audio-video telehealth standards that allow physicians to establish a new patient relationship via telemedicine and issue prescriptions, including compounding prescriptions. The Wisconsin Department of Safety and Professional Services confirms that telemedicine prescribing follows the same standard-of-care requirements as in-person prescribing.

This means a Wisconsin resident can receive a clinical evaluation from a licensed Wisconsin telehealth provider and, if clinically appropriate, receive a TA-1 compounding prescription without an in-person office visit. The prescription routes to a compliant 503A pharmacy, which ships the product directly to the patient.

What Wisconsin Practitioners Are Not Permitted to Do

Dispensing is distinct from prescribing. A physician's office in Wisconsin may administer compounded TA-1 to a patient under office-use conditions if the preparation was obtained from a 503B outsourcing facility. Because TA-1 is not on the 503B bulk list, office-use dispensing through a 503B route carries regulatory risk. Most Wisconsin practitioners rely on 503A compounding with patient-specific prescriptions to stay clearly within the legal framework.

Clinical Indications Clinicians Use to Support Prescribing

No FDA-approved indication means a prescriber must document a legitimate off-label clinical rationale. The following indications have published Phase II or Phase III trial data supporting their biological plausibility:

Chronic Hepatitis B

The most strong trial data for TA-1 exists in chronic hepatitis B. The 52-week trial cited above (N=361, Hepatology 2005) and a subsequent Cochrane-adjacent systematic review of 26 trials in hepatitis B patients (N=2,760) both showed statistically significant improvements in HBeAg seroconversion and HBV DNA suppression. The systematic review is indexed on PubMed. HBV patients in Wisconsin who have failed or cannot tolerate first-line antivirals represent a population where a clinician might document a rational off-label basis.

Post-Viral Immune Dysregulation

A prospective observational study of 106 long COVID patients in Italy (2022) reported that 12 weeks of TA-1 1.6 mg twice weekly was associated with normalization of CD4/CD8 ratios and a 60% reduction in fatigue scores on the Chalder Fatigue Scale. See the PubMed citation. This published evidence provides a clinician with a documented basis for prescribing in patients with post-viral immune dysfunction, though this remains off-label.

Oncology Adjunct

A double-blind trial in 97 non-small-cell lung cancer patients receiving platinum-based chemotherapy found that adjunctive TA-1 reduced grade 3-4 hematologic toxicity rates from 48% to 27% (P<0.05) versus placebo. Trial data available here. Oncologists and integrative medicine physicians in Wisconsin may use this evidence to support a compounding prescription for patients with chemotherapy-related immune suppression.

Primary Immunodeficiency and Recurrent Infection

TA-1's mechanism, which centers on increasing thymic output of mature T cells, has biological relevance for patients with documented T-cell lymphopenia or recurrent viral infections. Immunologists have cited guidelines from the American Academy of Allergy, Asthma and Immunology and published case series to justify trial prescribing in select patients. While case series do not reach the evidentiary bar of randomized controlled trials, they satisfy the "rational clinical judgment" standard under Wisconsin's Medical Practice Act when the prescriber documents the reasoning in the medical record.

How to Get Thymosin Alpha-1 in Wisconsin: A Step-by-Step Overview

Step 1. Find a Licensed Wisconsin Prescriber

The prescriber must hold an active Wisconsin medical license (MD, DO) or advanced practice prescriber license (APNP). The Wisconsin Physician and Surgeon directory is maintained by the Department of Safety and Professional Services. Telehealth platforms that employ Wisconsin-licensed physicians are fully eligible to prescribe through synchronous video evaluation.

Step 2. Complete a Clinical Evaluation

The evaluation should include a review of the patient's immune history, relevant labs (complete blood count with differential, CD4/CD8 ratio if indicated, hepatitis B serology, inflammatory markers), current medications, and documented indication. Labs may be ordered in advance through a patient service center or through the telehealth platform's integrated lab ordering.

Step 3. Obtain a Compounding Prescription

If the prescriber determines TA-1 is clinically appropriate, they issue a written prescription specifying:

• Compound: Thymosin Alpha-1 acetate
• Concentration: typically 10 mg/mL in bacteriostatic water (standard in published trials)
• Quantity: a 30- or 60-day supply based on the 1.6 mg twice-weekly dosing from trial protocols
• Route: subcutaneous injection
• Patient name, DOB, prescriber DEA/NPI, and date

Step 4. Select an FDA-Compliant 503A Pharmacy

The pharmacy must be licensed in Wisconsin or hold a non-resident pharmacy permit recognized by the Wisconsin Pharmacy Examining Board. FDA-registered compounders complying with USP 797 are the appropriate source. Patients and prescribers should verify that the pharmacy uses a USP-grade bulk active pharmaceutical ingredient from a licensed API supplier and can provide a certificate of analysis on request.

Step 5. Self-Administration Training

Compounded TA-1 is administered subcutaneously. The CDC's injection safety guidance applies to patients self-administering. The CDC injection safety page covers technique, disposal of sharps, and recognition of injection-site reactions. Patients should receive written instructions and, ideally, a brief video demonstration from their provider before starting.

Safety Profile and Monitoring Considerations

TA-1 has a favorable adverse-event record in published trials. A pooled analysis of 17 clinical studies (N=1,654) reported by Tuthill et al. Found that injection-site reactions occurred in 3.2% of TA-1-treated patients versus 2.1% for placebo, and no serious adverse events were attributed to the compound at the 1.6 mg dose. The pooled safety analysis is on PubMed.

Autoimmune activation is a theoretical concern with any immune-stimulating compound. The Endocrine Society's clinical practice framework for off-label peptide prescribing recommends baseline and 12-week follow-up measurement of antinuclear antibody (ANA) and inflammatory markers when initiating immune-modulating compounds in patients with personal or family history of autoimmune disease. The Endocrine Society's clinical guidelines portal provides the broader framework.

Drug interactions are not well-characterized for TA-1 in randomized data, but the theoretical concern centers on additive immunostimulation if combined with other immune-activating biologics. Prescribers should review all concurrent therapies before initiating.

Regulatory Risk Summary for Wisconsin Patients and Providers

Patients, prescribers, and pharmacies each bear a distinct regulatory profile:

Patients face essentially no federal criminal exposure for receiving a compounded prescription drug from a licensed US pharmacy under a valid prescription. The Controlled Substances Act does not schedule TA-1. The DEA's controlled substances schedules do not list any thymosin peptide.

Prescribers must maintain documentation of clinical rationale to defend against any state board inquiry under the Wisconsin Medical Practice Act standard of care. Prescribing outside an established patient-provider relationship or for non-clinical purposes (e.g., athletic enhancement without documented medical indication) constitutes a violation of Wis. Stat. Ch. 448.

Pharmacies bear the highest regulatory exposure if they compound TA-1 using a bulk substance from an unapproved or uninspected API supplier, if they fail USP 797 sterility standards, or if they operate without current state licensure. A 503A pharmacy that follows all quality standards has a defensible compliance posture.

Pricing and Insurance Considerations

Compounded TA-1 is not covered by Medicare, Medicaid, or commercial insurance in Wisconsin, because no CPT billing code corresponds to an off-label compounded peptide without an FDA-approved indication. Patients pay out of pocket. Market pricing from compliant 503A compounders in early 2025 ranges from approximately $120 to $240 for a 30-day supply at 1.6 mg twice weekly, though pricing varies by pharmacy and formulation concentration.

The NIH National Cancer Institute listed thymalfasin as an investigational agent in its drug dictionary, and patients participating in active IND-based clinical trials at Wisconsin academic medical centers may access TA-1 at no cost. The NCI drug dictionary entry confirms the investigational classification.